Today: 7 February 2026
Subscribe
Browse Category

NYSE:BSX News 23 January 2026 - 7 February 2026

Boston Scientific stock price slips again after earnings shock as BSX investors eye heart-rhythm sales

Boston Scientific stock price slips again after earnings shock as BSX investors eye heart-rhythm sales

Boston Scientific shares closed down 1.8% at $76.27 Friday, near post-earnings lows after a 17% plunge Wednesday on weak electrophysiology sales and a softer 2026 outlook. Trading volume reached 34.9 million shares. The stock lagged peers as the S&P 500 rose about 2%. Investors are watching early-quarter demand signals ahead of the next earnings update in late April.
7 February 2026
····
Boston Scientific stock rebounds after earnings shock as analysts cut targets on EP worries

Boston Scientific stock rebounds after earnings shock as analysts cut targets on EP worries

Boston Scientific shares rose 2.8% to $77.64 in Thursday’s after-hours trading, rebounding after a record 17% plunge Wednesday on weak Q4 electrophysiology and Watchman sales. Citi and Wells Fargo lowered price targets but kept positive ratings. Fourth-quarter net sales reached $5.29 billion, with adjusted EPS of $0.80. The company expects 2026 adjusted EPS of $3.43–$3.49.
6 February 2026
·····
Boston Scientific stock rebounds after brutal selloff — what Wall Street watches next

Boston Scientific stock rebounds after brutal selloff — what Wall Street watches next

Boston Scientific shares rebounded 3.3% Thursday to $77.97 after plunging 17% Wednesday, their steepest one-day drop in over 25 years, following a sales miss in the electrophysiology unit. The company reported Q4 net sales of $5.29 billion and forecast 2026 adjusted earnings of $3.43–$3.49 per share with 10–11% organic sales growth.
5 February 2026
·····
Boston Scientific stock tries to steady after an 18% earnings drop put EP business on edge

Boston Scientific stock tries to steady after an 18% earnings drop put EP business on edge

Boston Scientific shares rose about 1% in Thursday premarket trading after plunging 17.6% Wednesday on weak electrophysiology sales and a softer 2026 outlook. Q4 electrophysiology revenue missed analyst estimates, and U.S. Watchman sales fell short. The stock traded near $76.30 after closing at $75.50. CEO Michael Mahoney said Q4 results beat internal targets but warned of challenges in the first quarter.
5 February 2026
····
Boston Scientific (BSX) stock dives on electrophysiology sales miss — what to watch after the bell

Boston Scientific (BSX) stock dives on electrophysiology sales miss — what to watch after the bell

Boston Scientific shares fell nearly 18% in after-hours trading Wednesday after the company reported disappointing electrophysiology sales and lowered its 2026 growth outlook. U.S. demand for the Watchman implant also missed expectations. The company guided first-quarter adjusted EPS to $0.78–$0.80 and organic revenue growth of 8.5%–10%. Analysts are watching for further estimate cuts and commentary on heart-rhythm procedure trends.
4 February 2026
···
Boston Scientific stock price skids as key heart-rhythm sales miss jolts BSX

Boston Scientific stock price skids as key heart-rhythm sales miss jolts BSX

Boston Scientific shares fell 15% to $77.83 after quarterly electrophysiology sales missed Wall Street estimates, with Q4 revenue in that segment at $890 million versus a $933 million consensus. Analysts flagged fresh doubts about growth in electrophysiology and Watchman devices. The stock’s drop marked its sharpest one-day decline in over 25 years. Investors await Watchman “CHAMPION” trial data at the ACC.26 meeting in March.
4 February 2026
····
Boston Scientific stock slips today: what to know before earnings and key Watchman trial data

Boston Scientific stock slips today: what to know before earnings and key Watchman trial data

Boston Scientific (BSX.N) slipped 0.7% to $91.20 in Tuesday afternoon trading, with about 10.4 million shares exchanged. CEO Michael F. Mahoney filed to potentially sell up to 160,901 shares valued at $15 million. The company reports fourth-quarter earnings Wednesday morning. Investors await late-March CHAMPION-AF trial results for the Watchman device.
3 February 2026
····
Boston Scientific stock price drops today: BSX slides as investors size up Feb. 4 earnings, Watchman trial date

Boston Scientific stock price drops today: BSX slides as investors size up Feb. 4 earnings, Watchman trial date

Boston Scientific shares fell 1.6% to $92.01 Monday, lagging sector peers as the S&P 500 rose. Investors are watching for the company’s Feb. 4 earnings call and the March 28 release of CHAMPION-AF trial results for its Watchman device. TD Cowen maintained a buy rating, citing potential upside if the trial data proves positive.
2 February 2026
····
Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings

Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings

Boston Scientific shares fell 1.6% to $92.33 Thursday, ending a four-day rally on heavy volume after the company completed its acquisition of Nalu Medical. The stock underperformed sector peers as investors awaited fourth-quarter results due Feb. 4 and looked for updates on recent deal activity, including the $14.5 billion Penumbra purchase.
30 January 2026
········
ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy

ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy

Intuitive Surgical shares fell 0.7% to $525.09 Tuesday after the FDA cleared its da Vinci 5 robot for select cardiac procedures. The S&P 500 ETF rose 0.5% and QQQ gained 0.9%. TD Cowen initiated coverage with a Buy rating and $660 target, citing potential for expanded hospital adoption. Intuitive forecasts 13–15% da Vinci procedure growth in 2026, with a 1.2% revenue hit from tariffs.
27 January 2026
······
Boston Scientific (BSX) stock ticks higher again — what to watch before Tuesday’s trade

Boston Scientific (BSX) stock ticks higher again — what to watch before Tuesday’s trade

Boston Scientific shares rose 1.12% to $93.55 Monday, outperforming Medtronic but lagging Abbott and Stryker. The company faces FDA scrutiny over its AXIOS GI stent after reports of injuries and deaths. Investors are focused on the $14.5 billion Penumbra acquisition, expected to close in 2026. Quarterly results are due Feb. 4.
27 January 2026
·····
Boston Scientific stock (BSX) climbs as heart-rhythm rivalry and deal risk stay in play

Boston Scientific stock (BSX) climbs as heart-rhythm rivalry and deal risk stay in play

Boston Scientific shares rose about 1% to $92.20 Friday, outperforming a weaker healthcare sector as investors focused on pulsed-field ablation for atrial fibrillation. The company’s $14.5 billion deal to buy Penumbra and its upcoming Feb. 4 earnings report are drawing scrutiny. Johnson & Johnson posted $24.6 billion in quarterly sales and gave 2026 guidance, while Medtronic and Abbott shares fell.
23 January 2026
····
1 2 3

Stock Market Today

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

7 February 2026
London, February 7, 2026, 09:41 GMT — Market closed. Ashtead Group plc shares closed at 4,936 pence on Friday, up 1.09% on the day. The stock traded between 4,838p and 4,985p, with volume of about 1.1 million shares after a 2.6% drop on Thursday. (Share Prices) The moves matter now because Ashtead is preparing to shift its primary listing to New York through its Sunbelt Rentals structure, a change that can alter who owns the stock and where it trades. The company has said the SEC filing that starts the U.S. registration process is expected to become effective on Feb.
Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

7 February 2026
Beazley shares closed flat at 1,236 pence Friday as BlackRock disclosed a 6.55% stake and Vanguard reported 5.02%. Wellington Management cut its holding below 5%. The disclosures follow Zurich Insurance’s possible takeover offer of up to 1,335 pence per share, with a Feb. 16 deadline for a firm bid.
Go toTop